Open Access
| Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
|---|---|---|
| Article Number | 02013 | |
| Number of page(s) | 4 | |
| Section | Innovations in Therapeutics and Disease Mechanisms | |
| DOI | https://doi.org/10.1051/bioconf/202517402013 | |
| Published online | 12 May 2025 | |
- Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024. 74(3): p. 229-263. [CrossRef] [PubMed] [Google Scholar]
- Lin, X., et al., Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer, 2024. 23(1). [Google Scholar]
- Lin, M., et al., Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients. Journal of Clinical Investigation, 2020. 130(5): p. 2560-2569. [CrossRef] [PubMed] [Google Scholar]
- Liu, J., et al., Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application. European Journal of Pharmacology, 2024. 979. [Google Scholar]
- Das, S., et al., Structure-Activity Relationship Insight of Naturally Occurring Bioactive Molecules and Their Derivatives Against Non-Small Cell Lung Cancer: A Comprehensive Review. Current Medicinal Chemistry, 2022. 29(39): p. 6030-6062. [CrossRef] [Google Scholar]
- Li, C., et al., Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. Journal of Translational Medicine, 2019. 17(1). [Google Scholar]
- Reyes, A., R. Muddasani, and E. Massarelli, Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer. Cancers, 2024. 16(16). [Google Scholar]
- Budczies, J., et al., Tumour mutational burden: clinical utility, challenges and emerging improvements. Nature Reviews Clinical Oncology, 2024. [Google Scholar]
- Wang, Z., et al., Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients with Non–Small Cell Lung Cancer with Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 2019. 5(5). [Google Scholar]
- Seidel, J. A., A. Otsuka, and K. Kabashima, Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology, 2018. 8. [Google Scholar]
- Sumbly, V. and I. Landry, Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer. Cureus, 2022. [Google Scholar]
- Khwaja, R.M. and Q.S.C. Chu, Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review. Current Oncology, 2022. 29(2): p. 479-489. [CrossRef] [Google Scholar]
- Cai, R., et al., To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Journal of Cancer Research and Clinical Oncology, 2023. 149(12): p. 10027-10040. [CrossRef] [PubMed] [Google Scholar]
- Trulson, I., et al., Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update. Tumor Biology, 2024. 46(s1): p. S111-S161. [Google Scholar]
- Marinello, A., et al., Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer. Cancer Treatment Reviews, 2024. 129. [Google Scholar]
- Rolfo, C., et al., Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021. 16(10): p. 1647-1662. [CrossRef] [Google Scholar]
- David, J. M., et al., A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017. 6(10). [Google Scholar]
- Mariathasan, S., et al., TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018. 554(7693): p. 544-548. [CrossRef] [PubMed] [Google Scholar]
- Zitvogel, L., et al., Microbiome and Anticancer Immunosurveillance. Cell, 2016. 165(2): p. 276-287. [CrossRef] [Google Scholar]
- Jang, H. J., et al., Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer. Respiratory Research, 2021. 22(1). [CrossRef] [Google Scholar]
- Adugna, A., et al., Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non‐small cell lung cancer. Aging Medicine, 2024. 7(1): p. 121-130. [CrossRef] [Google Scholar]
- Garg, P., et al., Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions. Journal of Clinical Medicine, 2024. 13(14). [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.